Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Guardant Health, Inc.GH · Entity 3238 | Director · Co-Chief Executive Officer | September 30, 2026 | October 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Guardant Health, Inc.
Report date September 30, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectShares held by Talasaz and Eskandari 2017 Family Trust | 1,827,168 |
Reported balance
After 2026-09-30 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-09-30 · Exercise / conversion · Acquired 2,817 · Balance 1,827,168 |
| Common StockSEC Table I · non-derivative | IndirectShares held by Talasaz and Eskandari 2017 Family Trust | 1,825,740 |
Reported balance
After 2026-09-30 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-09-30 · Tax withholding · Disposed 1,428 · Balance 1,825,740 F1: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. |
| Common StockSEC Table I · non-derivative | IndirectShares held by Talasaz and Eskandari 2017 Family Trust | 1,849,737 |
Reported balance
After 2026-10-01 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2026-10-01 · Exercise / conversion · Acquired 23,997 · Balance 1,849,737 |
| Common StockSEC Table I · non-derivative | IndirectShares held by Talasaz and Eskandari 2017 Family Trust | 1,859,453 |
Reported balance
After 2026-10-01 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2026-10-01 · Exercise / conversion · Acquired 9,716 · Balance 1,859,453 |
| Common StockSEC Table I · non-derivative | IndirectShares held by Talasaz and Eskandari 2017 Family Trust | 1,842,366 |
Reported balance
After 2026-10-01 transaction · row 5
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 5 · 2026-10-01 · Tax withholding · Disposed 17,087 · Balance 1,842,366 F1: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 2,817 |
Reported balance
After 2026-09-30 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-09-30 · Exercise / conversion · Disposed 2,817 · Balance 2,817 F2: This represents a restricted stock unit award granted on March 17, 2026 that vests in four equal installments on the last day of each calendar quarter, March 31, 2026, June 30, 2026, September 30, 2026, and December 31, 2026. F3: Not applicable for Restricted Stock Units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 23,998 |
Reported balance
After 2026-10-01 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-10-01 · Exercise / conversion · Disposed 23,997 · Balance 23,998 F4: This represents a restricted stock unit award granted on March 18, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on January 1, 2025 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter. F3: Not applicable for Restricted Stock Units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 48,580 |
Reported balance
After 2026-10-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-10-01 · Exercise / conversion · Disposed 9,716 · Balance 48,580 F5: This represents a restricted stock unit award granted on March 12, 2025 that vests over a three-year period. 33% of the shares subject to such award vested on January 1, 2026 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter. F3: Not applicable for Restricted Stock Units. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability.
F2: This represents a restricted stock unit award granted on March 17, 2026 that vests in four equal installments on the last day of each calendar quarter, March 31, 2026, June 30, 2026, September 30, 2026, and December 31, 2026.
F3: Not applicable for Restricted Stock Units.
F4: This represents a restricted stock unit award granted on March 18, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on January 1, 2025 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.
F5: This represents a restricted stock unit award granted on March 12, 2025 that vests over a three-year period. 33% of the shares subject to such award vested on January 1, 2026 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 08, 2021 Filed Feb 10, 2021 00:21 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 28,995 | $163.03 | $4,727,104.14 |
DisclosureSEC source: 0001576280-21-000014 · wf-form4_161291648574061.xml · nonDerivative · entry 15 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,086,803 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F10 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $162.83 to $163.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 00:21 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 49,237 | $162.27 | $7,989,441.81 |
DisclosureSEC source: 0001576280-21-000014 · wf-form4_161291648574061.xml · nonDerivative · entry 14 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,115,798 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F9 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $161.83 to $162.825, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 00:21 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 14,416 | $161.49 | $2,328,041.28 |
DisclosureSEC source: 0001576280-21-000014 · wf-form4_161291648574061.xml · nonDerivative · entry 13 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,165,035 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F8 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $160.83 to $161.82, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 05, 2021 Filed Feb 10, 2021 00:21 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 1,161 | $163.03 | $189,282.71 |
DisclosureSEC source: 0001576280-21-000014 · wf-form4_161291648574061.xml · nonDerivative · entry 12 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Talasaz Investments, L.P. Disclosed balance after: 538,517 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F7 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $162.79 to $163.40, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 05, 2021 Filed Feb 10, 2021 00:21 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 19,096 | $162.34 | $3,100,084.74 |
DisclosureSEC source: 0001576280-21-000014 · wf-form4_161291648574061.xml · nonDerivative · entry 11 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Talasaz Investments, L.P. Disclosed balance after: 539,678 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $161.79 to $162.785, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 05, 2021 Filed Feb 10, 2021 00:21 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 4,825 | $161.07 | $777,144.42 |
DisclosureSEC source: 0001576280-21-000014 · wf-form4_161291648574061.xml · nonDerivative · entry 10 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Talasaz Investments, L.P. Disclosed balance after: 558,774 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $160.79 to $161.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 05, 2021 Filed Feb 10, 2021 00:21 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 4,512 | $160.03 | $722,035.06 |
DisclosureSEC source: 0001576280-21-000014 · wf-form4_161291648574061.xml · nonDerivative · entry 9 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Talasaz Investments, L.P. Disclosed balance after: 563,599 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $159.74 to $160.73, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 05, 2021 Filed Feb 10, 2021 00:21 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 406 | $159.25 | $64,656.39 |
DisclosureSEC source: 0001576280-21-000014 · wf-form4_161291648574061.xml · nonDerivative · entry 8 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Talasaz Investments, L.P. Disclosed balance after: 568,111 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $158.74 to $159.73, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 05, 2021 Filed Feb 10, 2021 00:21 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 84 | $157.84 | $13,258.56 |
DisclosureSEC source: 0001576280-21-000014 · wf-form4_161291648574061.xml · nonDerivative · entry 7 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Talasaz Investments, L.P. Disclosed balance after: 568,517 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $157.57 to $158.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 05, 2021 Filed Feb 10, 2021 00:21 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 10,373 | $163.01 | $1,690,855.01 |
DisclosureSEC source: 0001576280-21-000014 · wf-form4_161291648574061.xml · nonDerivative · entry 6 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,179,451 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F7 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $162.79 to $163.40, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 05, 2021 Filed Feb 10, 2021 00:21 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 126,582 | $162.31 | $20,545,018.09 |
DisclosureSEC source: 0001576280-21-000014 · wf-form4_161291648574061.xml · nonDerivative · entry 5 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,189,824 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $161.79 to $162.785, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 05, 2021 Filed Feb 10, 2021 00:21 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 32,240 | $161.07 | $5,192,803.30 |
DisclosureSEC source: 0001576280-21-000014 · wf-form4_161291648574061.xml · nonDerivative · entry 4 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,316,406 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $160.79 to $161.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 05, 2021 Filed Feb 10, 2021 00:21 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 30,028 | $160.03 | $4,805,308.77 |
DisclosureSEC source: 0001576280-21-000014 · wf-form4_161291648574061.xml · nonDerivative · entry 3 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,348,646 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $159.74 to $160.73, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 05, 2021 Filed Feb 10, 2021 00:21 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 2,071 | $159.37 | $330,048.23 |
DisclosureSEC source: 0001576280-21-000014 · wf-form4_161291648574061.xml · nonDerivative · entry 2 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,378,674 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $158.74 to $159.73, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 05, 2021 Filed Feb 10, 2021 00:21 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 567 | $157.84 | $89,495.28 |
DisclosureSEC source: 0001576280-21-000014 · wf-form4_161291648574061.xml · nonDerivative · entry 1 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,380,745 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $157.57 to $158.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 04, 2021 Filed Feb 5, 2021 22:03 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 211 | $160.12 | $33,785.47 |
DisclosureSEC source: 0001576280-21-000013 · wf-form4_161256258436886.xml · nonDerivative · entry 20 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Talasaz Investments, L.P. Disclosed balance after: 568,601 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F9 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $160.07 to $160.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 04, 2021 Filed Feb 5, 2021 22:03 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 2,054 | $159.58 | $327,768.28 |
DisclosureSEC source: 0001576280-21-000013 · wf-form4_161256258436886.xml · nonDerivative · entry 19 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Talasaz Investments, L.P. Disclosed balance after: 568,812 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F8 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $159.07 to $160.055, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 04, 2021 Filed Feb 5, 2021 22:03 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 2,689 | $158.76 | $426,909.94 |
DisclosureSEC source: 0001576280-21-000013 · wf-form4_161256258436886.xml · nonDerivative · entry 18 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Talasaz Investments, L.P. Disclosed balance after: 570,866 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F7 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $158.07 to $159.06, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 04, 2021 Filed Feb 5, 2021 22:03 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 2,016 | $157.76 | $318,048.60 |
DisclosureSEC source: 0001576280-21-000013 · wf-form4_161256258436886.xml · nonDerivative · entry 17 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Talasaz Investments, L.P. Disclosed balance after: 573,555 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $157.07 to $158.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 04, 2021 Filed Feb 5, 2021 22:03 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 1,228 | $160.12 | $196,625.27 |
DisclosureSEC source: 0001576280-21-000013 · wf-form4_161256258436886.xml · nonDerivative · entry 16 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,381,312 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F9 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $160.07 to $160.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 04, 2021 Filed Feb 5, 2021 22:03 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 14,051 | $159.58 | $2,242,292.30 |
DisclosureSEC source: 0001576280-21-000013 · wf-form4_161256258436886.xml · nonDerivative · entry 15 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,382,540 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F8 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $159.07 to $160.055, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 04, 2021 Filed Feb 5, 2021 22:03 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 18,180 | $158.76 | $2,886,289.52 |
DisclosureSEC source: 0001576280-21-000013 · wf-form4_161256258436886.xml · nonDerivative · entry 14 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,396,591 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F7 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $158.07 to $159.06, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 04, 2021 Filed Feb 5, 2021 22:03 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 13,594 | $157.76 | $2,144,627.50 |
DisclosureSEC source: 0001576280-21-000013 · wf-form4_161256258436886.xml · nonDerivative · entry 13 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,414,771 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $157.07 to $158.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 04, 2021 Filed Feb 17, 2021 22:22 UTC Amendment | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 1,315 | $160.12 | $210,557.14 |
DisclosureSEC source: 0001576280-21-000020 · wf-form4a_161360053573862.xml · nonDerivative · entry 3 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,381,657 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $160.07 to $160.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3 · ownership.direct: This amendment corrects minor errors regarding share amounts and/or prices. F6 · ownership.direct: Reflects updated direct holdings as of 02/04/2021 after giving effect to the corrections to the share amounts. Read SEC document |
| February 04, 2021 Filed Feb 17, 2021 22:22 UTC Amendment | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 13,874 | $159.59 | $2,214,118.36 |
DisclosureSEC source: 0001576280-21-000020 · wf-form4a_161360053573862.xml · nonDerivative · entry 2 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,382,972 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $159.07 to $160.055, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3 · ownership.direct: This amendment corrects minor errors regarding share amounts and/or prices. Read SEC document |
| February 04, 2021 Filed Feb 17, 2021 22:22 UTC Amendment | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 17,988 | $158.76 | $2,855,760.49 |
DisclosureSEC source: 0001576280-21-000020 · wf-form4a_161360053573862.xml · nonDerivative · entry 1 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,396,846 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $158.07 to $159.06, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3 · ownership.direct: This amendment corrects minor errors regarding share amounts and/or prices. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 22:03 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 9 | $160.55 | $1,444.95 |
DisclosureSEC source: 0001576280-21-000013 · wf-form4_161256258436886.xml · nonDerivative · entry 12 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Talasaz Investments, L.P. Disclosed balance after: 575,571 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 22:03 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 4,944 | $159.53 | $788,712.36 |
DisclosureSEC source: 0001576280-21-000013 · wf-form4_161256258436886.xml · nonDerivative · entry 11 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Talasaz Investments, L.P. Disclosed balance after: 575,580 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $159.37 to $160.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 22:03 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 1,657 | $158.75 | $263,049.08 |
DisclosureSEC source: 0001576280-21-000013 · wf-form4_161256258436886.xml · nonDerivative · entry 10 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Talasaz Investments, L.P. Disclosed balance after: 580,524 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $158.37 to $159.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 22:03 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 4,606 | $157.93 | $727,409.92 |
DisclosureSEC source: 0001576280-21-000013 · wf-form4_161256258436886.xml · nonDerivative · entry 9 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Talasaz Investments, L.P. Disclosed balance after: 582,181 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $157.3684 to $158.3606, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 22:03 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 246 | $156.94 | $38,606.13 |
DisclosureSEC source: 0001576280-21-000013 · wf-form4_161256258436886.xml · nonDerivative · entry 8 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Talasaz Investments, L.P. Disclosed balance after: 586,787 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $156.36 to $157.33, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 22:03 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 335 | $160.55 | $53,784.25 |
DisclosureSEC source: 0001576280-21-000013 · wf-form4_161256258436886.xml · nonDerivative · entry 7 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,428,365 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 22:03 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 32,638 | $159.54 | $5,206,988.19 |
DisclosureSEC source: 0001576280-21-000013 · wf-form4_161256258436886.xml · nonDerivative · entry 6 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,428,700 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $159.37 to $160.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 22:03 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 11,074 | $158.75 | $1,758,009.68 |
DisclosureSEC source: 0001576280-21-000013 · wf-form4_161256258436886.xml · nonDerivative · entry 5 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,461,338 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $158.37 to $159.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 22:03 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 31,156 | $157.93 | $4,920,348.69 |
DisclosureSEC source: 0001576280-21-000013 · wf-form4_161256258436886.xml · nonDerivative · entry 4 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,472,412 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $157.3684 to $158.3606, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 22:03 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 1,712 | $156.92 | $268,641.05 |
DisclosureSEC source: 0001576280-21-000013 · wf-form4_161256258436886.xml · nonDerivative · entry 3 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,503,568 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $156.36 to $157.33, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 00:33 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 2,128 | $159.53 | $339,479.20 |
DisclosureSEC source: 0001576280-21-000012 · wf-form4_161239879900811.xml · nonDerivative · entry 22 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Talasaz Investments, L.P. Disclosed balance after: 587,033 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F12 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $159.50 to $159.61, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 00:33 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 6,772 | $158.92 | $1,076,196.08 |
DisclosureSEC source: 0001576280-21-000012 · wf-form4_161239879900811.xml · nonDerivative · entry 21 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Talasaz Investments, L.P. Disclosed balance after: 589,161 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F11 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $158.22 to $159.19, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 00:33 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 8,440 | $157.65 | $1,330,535.62 |
DisclosureSEC source: 0001576280-21-000012 · wf-form4_161239879900811.xml · nonDerivative · entry 20 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Talasaz Investments, L.P. Disclosed balance after: 595,933 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F10 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $157.21 to $158.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 00:33 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 1,355 | $156.79 | $212,453.84 |
DisclosureSEC source: 0001576280-21-000012 · wf-form4_161239879900811.xml · nonDerivative · entry 19 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Talasaz Investments, L.P. Disclosed balance after: 604,373 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F9 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $156.21 to $157.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 00:33 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 803 | $155.87 | $125,167.14 |
DisclosureSEC source: 0001576280-21-000012 · wf-form4_161239879900811.xml · nonDerivative · entry 18 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Talasaz Investments, L.P. Disclosed balance after: 605,728 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F8 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $155.21 to $156.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 00:33 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 15,625 | $159.54 | $2,492,745.31 |
DisclosureSEC source: 0001576280-21-000012 · wf-form4_161239879900811.xml · nonDerivative · entry 17 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,622,883 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F12 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $159.50 to $159.61, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 00:33 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 43,478 | $158.91 | $6,909,275.94 |
DisclosureSEC source: 0001576280-21-000012 · wf-form4_161239879900811.xml · nonDerivative · entry 16 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,638,508 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F11 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $158.22 to $159.19, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 00:33 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 57,542 | $157.63 | $9,070,529.59 |
DisclosureSEC source: 0001576280-21-000012 · wf-form4_161239879900811.xml · nonDerivative · entry 15 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,681,986 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F10 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $157.21 to $158.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 00:33 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 9,619 | $156.79 | $1,508,132.23 |
DisclosureSEC source: 0001576280-21-000012 · wf-form4_161239879900811.xml · nonDerivative · entry 14 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,739,528 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F9 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $156.21 to $157.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 00:33 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 4,629 | $155.88 | $721,545.84 |
DisclosureSEC source: 0001576280-21-000012 · wf-form4_161239879900811.xml · nonDerivative · entry 13 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,749,147 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F8 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $155.21 to $156.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 02, 2021 Filed Feb 17, 2021 22:16 UTC Amendment | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 15,676 | $159.54 | $2,500,881.63 |
DisclosureSEC source: 0001576280-21-000019 · wf-form4a_161360015117611.xml · nonDerivative · entry 2 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,622,946 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $159.50 to $159.61, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3 · ownership.direct: This amendment corrects minor errors regarding share amounts and/or prices. F5 · ownership.direct: Reflects updated direct holdings as of 02/02/2021 after giving effect to the corrections to the share amounts. Read SEC document |
| February 02, 2021 Filed Feb 17, 2021 22:16 UTC Amendment | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 43,364 | $158.91 | $6,891,177.05 |
DisclosureSEC source: 0001576280-21-000019 · wf-form4a_161360015117611.xml · nonDerivative · entry 1 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,638,622 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $158.22 to $159.19, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3 · ownership.direct: This amendment corrects minor errors regarding share amounts and/or prices. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 00:33 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 28 | $157.02 | $4,396.61 |
DisclosureSEC source: 0001576280-21-000012 · wf-form4_161239879900811.xml · nonDerivative · entry 12 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Talasaz Investments, L.P. Disclosed balance after: 606,531 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F7 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $156.73 to $157.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 00:33 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 122 | $155.87 | $19,016.07 |
DisclosureSEC source: 0001576280-21-000012 · wf-form4_161239879900811.xml · nonDerivative · entry 11 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Talasaz Investments, L.P. Disclosed balance after: 606,559 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $155.69 to $156.33, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.